Josamycin

Infection caused by atypical pathogens such as mycoplasma and chlamydia has long been a difficulty in clinical medication for respiratory and urogenital systems. As a 16-membered ring macrolide antibiotic, josamycin inhibits protein synthesis by binding to the 50S subunit of bacterial ribosomes, and has the advantages of broad antibacterial spectrum, strong tissue permeability and low incidence of gastrointestinal adverse reactions. It has definite antibacterial activity against gram-positive bacteria and anaerobes, and remains sensitive to some erythromycin-resistant Staphylococcus aureus. It is clinically used for pharyngitis and tonsillitis caused by Streptococcus pyogenes, sinusitis, otitis media and acute bronchitis caused by sensitive bacteria, as well as mycoplasma pneumonia and urogenital tract infection caused by chlamydia, and the applicable population covers adult and pediatric patients with sensitive bacterial infections.

The global josamycin market size was approximately USD 210 million in 2023, and is expected to grow steadily at a compound annual growth rate of 3.2% from 2024 to 2030. The growth drivers mainly come from the increase in the diagnosis and treatment penetration rate of atypical pathogen infections in primary healthcare, as well as the release of demand for antibacterial drugs in the animal husbandry and aquaculture industry. In terms of competitive landscape, East Asia is the main region with concentrated API production capacity. Chinese enterprises account for nearly 60% of the global API supply share by virtue of cost advantages. The domestic market has completed multiple rounds of provincial centralized procurement, and the bid-winning prices tend to be stable. With the advancement of generic drug consistency evaluation, the demand for compliant APIs continues to rise.

The original developer of josamycin is Yamanouchi Pharmaceutical Co., Ltd. of Japan (now Astellas Pharma), with the original brand name "Josamy". The core compound patent expired globally in the 1990s. The mainstream dosage forms of the original drug include tablets, capsules and dry suspensions, with common specifications of 50mg and 200mg. The original product has been included in the Japanese Pharmacopoeia reference preparation catalog, and the original preparation is not imported into China. At present, a number of generic drugs such as josamycin tablets and josamycin granules have been marketed in China. There are 3 domestic josamycin API registration numbers on the CDE API registration platform, 2 of which are in the status of "A" and can be used for associated review. (Data as of July 2025, please refer to the official CDE website for the latest information)

The standardization of diagnosis and treatment pathways for atypical pathogen infections has put forward stricter requirements for impurity control of APIs and preparations. CATO provides a full set of josamycin impurity reference standards. Most products are available from stock. Stock products ordered before 16:00 will be shipped on the same day. They meet the compliance requirements of multiple regulations including the Chinese Pharmacopoeia and FDA, and can fully support enterprises' needs for API quality research, generic drug consistency evaluation and daily quality release testing.